With increased investment, growing clinical momentum, and advances in engineering and translational sciences, the bispecific field is growing faster than ever. Experts project the market will exceed $163 billion by 2032, highlighting continued demand across oncology, immunology, and beyond.
Despite this momentum, key challenges remain, from balancing manufacturability, safety, and differentiation to overcoming target heterogeneity and managing on-target off-tumour toxicity.
At this crucial time, I’m excited to announce the launch of the inaugural World Bispecific Summit Europe, taking place 7-9 July 2026 in London.
Building on the success of our long-running US meeting, this forum brings together Europe’s bispecific leaders to share practical, actionable strategies for multispecific design, targeting and translation.
These insights will help to expand the therapeutic window, de-risk development, and accelerate the delivery of safer, more effective bispecific candidates into the clinic.
Be the first to view the brand-new agenda for 2026!
This year’s agenda brings together 25+ expert speakers (14 of whom will be unveiling never-before-seen data) to share insights to improve efficacy while enhancing safety and toxicity profiles. Featured speakers include:
- Simon Plyte, Chief Scientific Officer, Biomunex Pharmaceuticals
- Matthew Lambert, Senior Director, Pfizer
- Christopher Lloyd, Director, AstraZeneca
- Arne Scheu, Chief Executive Officer, Valink Therapeutics
- Martin Steegmaier, Chief Scientific Officer, Molecular Partners
- Kristel Kemper, Director, Team Lead Early Translational Medicine & Research, Genmab
This is your opportunity to join Europe’s bispecific leaders to exchange real-world insights and discuss strategies that directly inform how multispecific programmes are designed and translated toward the clinic.
Browse the full speaker line-up and session details here.
We look forward to meeting you in London!
